Sales@medsciencepharm.com    +86-396-2967988
Cont

Have any Questions?

+86-396-2967988

Jun 30, 2025

Urokinase: A Life-Saving Thrombolytic Agent

Introduction

  • Urokinase is a fibrinolytic (thrombolytic) drug used to dissolve blood clots.
  • It was originally isolated from human urine (hence its name) but is now produced from human kidney cell cultures.
  • It plays a critical role in emergency medicine, especially in treating life-threatening blood clots.

 

Mechanism of Action

  • Urokinase is a serine protease enzyme.
  • It works by converting plasminogen → plasmin, the active enzyme that breaks down fibrin, the main structural protein in blood clots.
  • This results in clot dissolution and restored blood flow.

 

Clinical Uses

1. Pulmonary Embolism (PE) – dissolves clots in the lungs.

2. Deep Vein Thrombosis (DVT) – restores venous circulation.

3. Catheter Clearance – used in small doses to clear occluded IV catheters.

4. Off-label: sometimes considered for peripheral arterial occlusion and other thrombotic conditions.

 

Dosage & Administration

  • Administered intravenously under close monitoring.
  • Dosing depends on indication (e.g., higher for PE, lower for catheter clearance).
  • Continuous infusion is often used for systemic thrombolysis.

 

Advantages

  • Direct plasminogen activator (unlike streptokinase, it does not require a cofactor).
  • Human-derived → lower risk of allergic reactions compared to bacterial products like streptokinase.
  • Effective in dissolving fresh clots rapidly.

 

Risks & Side Effects

  • Major risk: bleeding (intracranial hemorrhage, gastrointestinal bleeding).
  • Hypotension and fever may occur.
  • Contraindications: recent surgery, active bleeding, history of hemorrhagic stroke, uncontrolled hypertension.

 

Life-Saving Impact

  • By restoring blood flow in blocked vessels, urokinase can prevent tissue death, organ failure, and fatal complications.
  • It has been especially valuable in massive pulmonary embolism, where rapid clot removal is crucial.

 

Conclusion

Urokinase remains a vital thrombolytic agent in clinical practice.
Its ability to rapidly dissolve blood clots makes it a life-saving intervention in emergencies, though careful patient selection and monitoring are essential to balance the benefits with the risk of bleeding.

 

Send Inquiry